Reporting Groups

	Description
Febuxostat 40 mg QD	Febuxostat 40 mg orally, once daily, based on serum urate level.
Febuxostat 80 mg QD	Febuxostat 80 mg, orally, once daily, based on serum urate level
Febuxostat 120 mg QD	Febuxostat 120 mg, orally, once daily, based on serum urate level

Baseline Measures

	Febuxostat 40 mg QD	Febuxostat 80 mg QD	Febuxostat 120 mg QD	Total
Number of Participants   [units: participants]	8	79	29	116
Age, Customized   [units: Subjects]
<45 years	2	20	9	31
45 to <65 years	4	40	15	59
≥65 years	2	19	5	26
Age   [units: years] Mean ± Standard Deviation	54.5 ± 11.44	53.9 ± 12.85	51.3 ± 13.01	53.3 ± 12.74
Gender   [units: subjects]
Female	0	9	2	11
Male	8	70	27	105
History of Kidney Stone   [units: Subjects]
Yes	0	11	3	14
No	8	68	26	102
Presence of Tophus   [units: Subjects]
Yes	1	13	12	26
No	7	66	17	90
Race/Ethnicity   [units: Subjects]
Asian	0	0	2	2
Black or African American	1	5	3	9
White	7	71	21	99
Hispanic	0	2	1	3
Other	0	1	2	3
Renal Function[1] [units: Subjects]
Normal	3	33	12	48
Impaired	5	46	17	68
Urine Uric Acid   [units: Subjects]
Underexcretor	5	62	21	88
Overproducer	3	16	7	26
Missing	0	1	1	2
Body Mass Index   [units: kiligram per meter² (kg/m²)] Mean ± Standard Deviation	28.4 ± 2.78	32.9 ± 5.28	33.9 ± 6.82	32.9 ± 5.69
Serum Urate   [units: mg/dL] Mean ± Standard Deviation	9.58 ± 1.18	9.48 ± 1.04	10.23 ± 1.74	9.7 ± 1.30

1.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 6 Visit.

2.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 12 Visit.

3.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 18 Visit.

4.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 24 Visit.

5.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 36 Visit.

6.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 48 Visit.

7.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Month 60 Visit.

8.  Primary:

Percentage of Subjects Whose Serum Urate Level Decreases to or is Maintained at <6.0 mg/dL at Final Visit.

9.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Month 6 Visit.

10.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Month 12 Visit.

11.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Month 18 Visit.

12.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Month 24 Visit.

13.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Month 36 Visit.

14.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Month 48 Visit.

15.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Month 60 Visit.

16.  Secondary:

Percent Change in Serum Urate Levels From Baseline at Final Visit.